Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease

Abstract

Background and Aims Anti-tumour necrosis factor [anti-TNF] therapy is indicated for treatment of moderate to severe inflammatory bowel disease [IBD], but has a primary non-response rate of around 30%. We aim to use metabonomic and metataxonomic profiling to identify predictive biomarkers of anti-TNF response in Crohn’s disease. Methods Patients with luminal Crohn’s disease, commencing anti-TNF therapy, were recruited with urine, faeces, and serum samples being collected at baseline and 3-monthly. Primary response was defined according to a combination of clinical and objective markers of inflammation. Samples were measured using three UPLC-MS assays: lipid, bile acid, and Hydrophillic Interaction Liquid Chromatography [HILIC] profiling with 16S rRNA gene sequencing of faeces. Results Samples were collected from 76 Crohn’s disease patients who were anti-TNF naïve and from 13 healthy controls. There were 11 responders, 37 non-responders, and 28 partial responders in anti-TNF-treated Crohn’s patients. Histidine and cysteine were identified as biomarkers of response from polar metabolite profiling [HILIC] of serum and urine. Lipid profiling of serum and faeces found phosphocholines, ceramides, sphingomyelins, and triglycerides, and bile acid profiling identified primary bile acids to be associated with non-response to anti-TNF therapy, with higher levels of phase 2 conjugates in non-responders. Receiver operating curves for treatment response demonstrated 0.94 +/ -0.10 [faecal lipid], 0.81 +/- 0.17 [faecal bile acid], and 0.74 +/- 0.15 [serum bile acid] predictive ability for anti-TNF response in Crohn’s disease. Conclusions This prospective, longitudinal cohort study of metabonomic and 16S rRNA gene sequencing analysis demonstrates that a range of metabolic biomarkers involving lipid, bile acid, and amino acid pathways may contribute to prediction of response to anti-TNF therapy in Crohn’s disease. Podcast This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast

Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease

“…In addition, one of the most pursued aims is to identify biomarkers that can predict whether an IBD patient will be a responder or a non-responder to one conventional therapy. Of interest, Ding and colleagues have recently reported a set of metabolites involving lipid, bile acid and amino acid pathways, which might contribute to predict the response to anti-TNF therapy [114]. This elegant study represents the starting point of a promising strategy in order to stablish some metabolites as predictors of the efficacy of the pharmacological treatment assigned to each IBD patient.…”

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?

“…Disturbances in an association network containing taxa of the Lachnospiraceae and Ruminococcaceae families, typically producing short chain fatty acids, were shown to characterize poor primary responses to treatment with anti-TNF-α therapeutic antibodies ( 106 ). A recently published prospective, longitudinal cohort study in CD patients identified metabolic profiles, which were predictive of primary anti-TNF non-response with alterations in bile acid, amino acid, and lipid pathways ( 107 ).…”

IBD metabonomics predicts phenotype, disease course, and treatment response

“…A more consistent finding is the identification of quiescent UC as a distinct metabonomic phenotype compared with patients with active disease and healthy control individuals [18À21]. Furthermore, recent studies have also demonstrated metabonomics as a potential clinical tool for predicting relapse [22] and response to treatment with biologics [23] as well as fecal microbiome transplantation (FMT) [24], thus facilitating proactive medical care.…”